https://www.selleckchem.com/pr....oducts/luzindole.htm
Around one-fifth of patients with schizophrenia have significant depression during the phase of clinical remission. It has a negative impact on functioning, is associated with a higher level of disability in the domain of interpersonal activities, and poor quality of life compared to those without significant depression. Hence, addressing depression should be an integral part of schizophrenia management in clinical remission to improve the overall outcome of patients with schizophrenia. Around one-fifth of patients with schizophrenia
إعجاب
علق
شارك
